Company | Reagent | Link to information | Remarks |
BioMedica Diagnostics | ACTICLOT C |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix |
|
Chromogenix | Coamatic Protein C |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference of heparin levels up tot 3 IU/ml |
|
Helena Biosciences | Protein C |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix |
|
Hyphen BioMed | Biophen Protein C LRT | Hyphen Biophen Protein C LRT |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference for heparin < 1 IU/mL, bilirubin < 60 mg/dL, hemoglobin < 500 mg/dL and intralipids concentration < 1000 mg/dL. Aprotinin or presence of anti-human Protein C antibodies may decrease the measured Protein C activity. |
Hyphen BioMed | Biophen Protein C | Hyphen Biophen Protein C 5 |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference for heparin < 1 IU/mL, bilirubin < 60 mg/dL, hemoglobin < 500 mg/dL and intralipids concentration < 1000 mg/dL. Aprotinin or presence of anti-human Protein C antibodies may decrease the measured Protein C activity. |
Hyphen BioMed | Hemoclot Protein C | Hyphen Hemoclot Protein C |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference for heparin < 1 IU/mL. Special caution should be taken for patients with known high levels of FVIII:C or with LA |
Nordic Biomarker | MRX Protein C |
Method: Chromogenic Activator: Protein C activator Interferences: No interference from heparin < 2 U/ml, bilirubin ≤20 mg/dL, haemoglobin ≤200 mg/dL, triglycerides ≤350 mg/dL |
|
Pentapharm | Protac | Protac |
Method: Chromogenic and clotting Activator: Derived from the venom of the viper agkistrodon contortrix |
Precision Biologic | Cryocheck Clot C | Precision Biologic Cryocheck Clot C |
Method: Clotting Activator: Russell’s viper venom (RVV-X) Interferences: No interference of factor VIII:C activity levels < 600% and heterozygous factor VLeiden mutation |
Renam | Reachrom protein C |
Method: Chromogenic |
|
Roche | Protein C Chrom | Roche Protein C Chrom |
Method: Chromogenic Activator: Snake venom |
Siemens Healthineers | Berichrom Protein C | Siemens Berichrom Protein C |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: False low protein C activity may be obtained in patients being treated with aprotinin |
Siemens Healthineers | Protein C Reagent | Siemens Protein C Reagent |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: False low protein C activity may be obtained in patients being treated with aprotinin. |
Stago | STA_Stachrom Protein C | Stago STA Stacrom Protein C |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference from hemoglobin < |
Stago | STA-Staclot Protein C | Stago STA-Staclot Protein C |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference from heparin < 1 U/ml, LA, factor VIII:C activity levels < 250%. Trombin inhibitors may interference |
Stago, Tcoag | TriniCLOT Protein C II | Stago TriniCLOT Protein C II |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix |
Technoclone | Technochrom Protein C | Technoclone Technochrom Protein C |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference from heparin < 2 U/ml |
Technoclone | Technoclot Protein C | Technoclone Technoclot Protein C |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix |
Werfen | HemosIL Proclot | Werfen HemosIL ProClot |
Method: Clotting Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: No interference from heparin (LMW) up to 0.7 U/mL, heparin (UF) up to 1.5 U/mL, hemoglobin < 200 mg/dL, bilirubin < 25 mg/dL and triglycerides < 600 mg/dL. |
Werfen | HemosIL Protein C | Werfen HemosIL Protein C |
Method: Chromogenic Activator: Derived from the venom of the viper agkistrodon contortrix Interferences: no interference from heparin (UF or LMW heparin) < 2 U/mL, |
- Special Information
- Calendar
- Assays
- Fibrinogen
- APTT
- Factor IX chromogenic methods
- PT/INR
- Antithrombin activity
- Antithrombin antigen
- Protein C activity
- Protein C antigen
- Protein S activity
- Protein S antigen (Free)
- Protein S antigen (Total)
- Activated protein C resistance ratio
- Protein C pathway test
- Lupus anticoagulant
- Antiphospholipid antibodies (Anticardiolipin)
- Antiphospholipid antibodies (α2-Glycoprotein I)
- D-Dimer
- Activator VIII IX XI XII
- Deficient plasma VIII IX XI XII
- Factor IX antigen
- Calibrators VIII IX XI XII
- Factor VIII antigen
- Factor VIII chromogenic methods
- Activator II V VII X
- Prothrombin (factor II) chromogenic methods
- Deficient plasma II V VII X
- Calibrators II V VII X
- VWF antigen
- VWF collagen binding assay
- VWF multimers
- VWF Activity
- VWF:RiCoF
- Factor XIII activity
- Factor XIII antigen
- Factor VIII deficient plasma
- Normal pooled plasma
- Immunological test
- Plasminogen activity
- Plasminogen antigen
- Plasmin inhibitor activity
- PAI-1 antigen
- PAI-1 activity
- t-PA antigen
- t-PA activity
- Method homocysteine
- ECAT Newsletter
- Terminology
- Links